Reason for request
The actual benefit provided by LORAMYC in the treatment of oropharyngeal candidiasis in immunocompromised patients, in particular patients with upper aerodigestive tract cancer after radiotherapy and in HIV infected patients is substantial.
Clinical Added Value
|no clinical added value||
LORAMYC, a muco-adhesive buccal tablet containing miconazole, does not provide improvement in actual benefit compared to miconazole oral gel (IAB V).
Nevertheless, the Committee emphasizes that this new pharmaceutical formulation represents a useful treatment option for patients.